D-0330-2023 Class II Ongoing

Recalled by Dr. Reddy's Laboratories, Inc. — Princeton, NJ

FDA drug recall D-0330-2023 was initiated by Dr. Reddy's Laboratories, Inc. on Feb 8, 2023 and is designated Class II. Reason for recall: Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules. The recall status is ongoing. Affected quantity: 4,320 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 1, 2023
Initiation Date
Feb 8, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
4,320 bottles

Product description

Tacrolimus Capsules, USP, 0.5 mg, 100-count bottle, Rx Only, Mfd. by Dr. Reddy's Laboratories Limited, Bachupally - 500 090, INDIA; NDC 55111-525-01.

Reason for recall

Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules.

Distribution pattern

Nationwide in the USA

Code information

Lot # C2106445; Exp. 03/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0330-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0330-2023. Report a data issue: hello@regdatalab.com.